ArticleArchive of clinical cases2025

Pembrolizumab-induced simultaneous and multiple immune-related adverse events including myasthenia gravis, myositis, hepatitis, and pityriasis lichenoides in a non-small cell lung cancer patient.

Mi-Ran Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.